| Literature DB >> 24131104 |
Giuseppe Manfroni1, Rolando Cannalire, Maria Letizia Barreca, Neerja Kaushik-Basu, Pieter Leyssen, Johan Winquist, Nunzio Iraci, Dinesh Manvar, Jan Paeshuyse, Rupa Guhamazumder, Amartya Basu, Stefano Sabatini, Oriana Tabarrini, U Helena Danielson, Johan Neyts, Violetta Cecchetti.
Abstract
We have previously reported that the 6-aminoquinolone chemotype is a privileged scaffold to obtain antibacterial and antiviral agents. Herein we describe the design, synthesis, and enzymatic and cellular characterization of new 6-aminoquinolone derivatives as potent inhibitors of NS5B polymerase, an attractive and viable therapeutic target to develop safe anti-HCV agents. The 6-amino-7-[4-(2-pyridinyl)-1-piperazinyl]quinolone derivative 8 proved to be the best compound of this series, exhibiting an IC50 value of 0.069 μM against NS5B polymerase and selective antiviral effect (EC50 = 3.03 μM) coupled with the absence of any cytostatic effect (CC50 > 163 μM; SI > 54) in Huh 9-13 cells carrying a HCV genotype 1b, as measured by MTS assay. These results indicate that the 6-aminoquinolone scaffold is worthy of further investigation in the context of NS5B-targeted HCV drug discovery programs.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24131104 PMCID: PMC3954902 DOI: 10.1021/jm401362f
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446